Advancing science to improve patient care and public health

Advancing science to improve patient care and public health.

Our Mission

Tonix Pharmaceuticals is committed to improving the lives of patients by identifying, researching and developing promising therapies which have the potential to address unmet needs.

We are developing both small molecule drugs and biologics across a range of therapeutic areas, focusing on prevention and treatment of immunology conditions, rare diseases, infectious diseases, and central nervous system disorders.

To learn more About Us, view our video.

About Tonix Pharmaceuticals

Tonix has a robust pipeline of programs in development stages ranging from preclinical to mid-Phase 3, across multiple therapeutic modalities, employing varied routes of administration. Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic.

While many of Tonix’s product candidates are proprietary, in-house developments, it also has collaborations with world-class academic and non-profit research organizations as well as license agreements with other biotech companies.

Therapeutic Areas

Central Nervous System

Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.

Immunology

We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*

Infectious Disease

Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.

Rare Disease

Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.

Central Nervous System

Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.

Immunology

We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*

Infectious Disease

Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.

Rare Disease

Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.

Pipeline Highlights

Using our integrated clinical development engine, we advance innovative programs into the clinic while maximizing asset potential.

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling

Mid-Phase III

TNX-1300   Cocaine Intoxication / Overdose
Phase II ready

Phase II

TNX-1840/TNX-1850   COVID-19 Vaccine

Preclinical

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 2H 2022

Preclinical

Management Team

“Many frontiers remain in the fields of medical science and drug development. At Tonix, we have carefully chosen pursuits in immunology, rare diseases, infectious diseases, and central nervous system disorders. We are building capabilities in synthetic biology, precision medicine, protein engineering, and vaccine manufacturing to develop better and safer medicines. Our ultimate goals are to improve and extend the lives of millions of people and, importantly, to reward the dedication and commitment of our stakeholders.”
— Dr. Seth Lederman, M.D., President and CEO, Tonix Pharmaceuticals

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.